EHVVF (EHVVF) Stock Price & Analysis
EHVVF (EHVVF) fell 40.00% to USD 0 as of July 25, 2026 at 13:46 UTC, according to Nexqual real-time market data.
EHVVF last closed at USD 0; the session ranged USD 0–0 on volume of 598,673 shares. Market capitalization is $1.33M, with a 52-week range of USD 0–0.01 (OID). Source: Nexqual, July 25, 2026 at 13:46 UTC.
Key Statistics (as of July 25, 2026 at 13:46 UTC)
| Price | USD 0 |
|---|---|
| Change | ▼ 40.00% (down) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.01 |
| Volume | 598,673 shares |
| Market Cap | $1.33M |
| Exchange | OID |
Technical Analysis (EHVVF)
Nexqual's technical model rates EHVVF "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 13:46 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.58 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (EHVVF)
Wall Street analysts rate EHVVF "None", per Nexqual as of July 25, 2026 at 13:46 UTC.
| Consensus Rating | None |
|---|
Earnings (EHVVF)
Source: Nexqual, July 25, 2026 at 13:46 UTC.
Financials & Fundamentals (EHVVF)
| Total Revenue | $2,183 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -91275.18% |
| Profit Margin | +0.00% |
| Current Ratio | 0.06 |
| Total Cash | $791,432 |
| Total Debt | $1.87M |
| Free Cash Flow | $2.13M |
Source: Nexqual, July 25, 2026 at 13:46 UTC.
Financial Health Score (EHVVF)
Nexqual rates EHVVF's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 13:46 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $791K cash vs $2M debt |
| Cash Flow | Strong — FCF $2M, 97462% margin |
| Efficiency | Mixed — No data |
Ownership (EHVVF)
| Insider Ownership | +70.07% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 1.48B |
| Float | 443.55M |
Source: Nexqual, July 25, 2026 at 13:46 UTC.
Leadership (EHVVF)
EHVVF is led by Benjamin Kaplan (age 57), President, CEO & Director, per Nexqual as of July 25, 2026 at 13:46 UTC.
| President, CEO & Director | Benjamin Kaplan (age 57) |
|---|---|
| Director of Investor & Public Relations | Gabriel P. Rodriguez |
| Director of Sales & Customer Acquisition | Patrick Gallagher |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RVVTF | Revive Therapeutics Ltd. | USD 0.02 | ▼ 14.29% |
| HAVLF | HAVN LIFE SCIENCES INC. | USD 0 | ▲ 0% |
| MYCOF | MYDECINE INNOVATIONS GROUP INC | USD 0.8 | ▲ 0% |
| TRUFF | Red Light Holland Corp. | USD 0.02 | ▼ 8.33% |
| PSYC | PSYC Corporation | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 13:46 UTC. This page is informational and not investment advice.